Literature DB >> 2475257

Anti-CD4 monoclonal antibodies enhance phorbol 12-myristate, 13-acetate-induced activation of human T cells.

J Favero1, J F Dixon, P C Bishop, J W Parker.   

Abstract

Evidence exists which indicates that the T cell differentiation molecule CD4 may interact with nonpolymorphic determinants of major histocompatibility complex (MHC) class II antigens on accessory cells to stabilize the formation of a ternary complex formed by the T cell receptor (CD3-TcR), antigen, and MHC class II restriction element. However, there is also evidence which suggests alternative or additional functional roles of CD4 in the delivery of signals to T cells independent of MHC class II recognition. In the present study, we examined different anti-CD4 monoclonal antibodies (mAbs) for their ability to influence lymphocyte proliferation induced by phorbol 12-myristate, 13-acetate (PMA). We found that the response of human peripheral blood mononuclear cells to PMA could be enhanced by some anti-CD4 mAbs (OKT4, OKT4A) but not by others (G17-2). This enhancement was due neither to a direct action of the mAbs on the monocytes nor to intercellular crosslinking through an Fc-Fc receptor interaction. We also found that the binding of anti-CD did not influence the down-regulation of CD4 expression induced by PMA, ruling out any correlation between increased stimulation and CD4 modulation. Our results, taken together with those recently published on the ability of a soluble anti-CD4 mAb (B66) to induce lymphocyte activation by itself, provide evidence that CD4 antigen plays a positive functional role in T cell stimulation in addition to stabilizing the antigen-antigen receptor interaction.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2475257     DOI: 10.1016/0008-8749(89)90079-8

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  1 in total

1.  Functional characterization of skin-infiltrating lymphocytes in atopic dermatitis.

Authors:  U Reinhold; S Kukel; B Goeden; U Neumann; H W Kreysel
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.